Read the Publication  This week we profile a recent publication in Bioinformatics from Dr. Inanc Birol  (fourth from left) and Hamza Khan (sixth from left) at the Michael Smith Genome Sciences Centre. Can you provide a brief overview of your lab’s current research focus? We at the Bioinformatics Technology lab of BC Genome Sciences Centre, analyze high-throughput sequencing data to study genomes…
Read More
CannaRoyalty Corp.  and Aequus Pharmaceuticals Inc. today announced a collaboration (the “JV”) to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders. CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian clinicians to create truly differentiated products supported by…
Read More

REVIEW: Translational Control of Aberrant Stress Responses as a Novel Hallmark of Cancer

Altered mRNA translational control is emerging as a critical factor in cancer development and progression. Targeting specific elements of the translational machinery, such as mTORC1 or eIF4E, is emerging as a new strategy for innovative cancer therapy. While translation of most mRNAs takes place through cap-dependent mechanisms, a sub-population of cellular mRNA species, particularly stress-inducible mRNAs with highly structured 5′-UTR…
Read More
Women are underwhelmingly employed in science, technology, engineering and mathematics (STEM) fields. Not only women themselves, but governments and industries would benefit to realize the value of more women in such fields. The European Commission says that more women in information and communications technology (ICT), a STEM subfield, could increase the European Union’s GDP by nine billion euros per year.…
Read More

MSFHR Appoints Dr. Bev Holmes as President & CEO

The Michael Smith Foundation for Health Research (MSFHR) Board is pleased to announce that following an executive search process, Dr. Bev Holmes has been appointed as president and CEO. With an eight-year history of leadership within MSFHR, Bev is ideally suited to lead MSFHR as we grow our role as BC’s expert health research funding agency, and continue to develop…
Read More
Chinese hamster ovary (CHO) cells are the most widely used cell types for the production of therapeutic proteins in the biotechnology industry. These cells are grown in large vessels known as bioreactors, and the eventual productivity of industrial bioprocesses depends largely on maintaining healthy productive cells. The main mechanism by which cells lose their viability is known as apoptosis, which…
Read More
Mutated cancer antigens, or neoantigens, represent compelling immunological targets and appear to underlie the success of several forms of immunotherapy. While there are anecdotal reports of neoantigen-specific T cells being present in the peripheral blood and/or tumors of cancer patients, effective adoptive cell therapy (ACT) against neoantigens will require reliable methods to isolate and expand rare, neoantigen-specific T cells from…
Read More
Depolarization of neuroendocrine cells results in calcium influx, which induces vesicle exocytosis and alters gene expression. These processes, along with the restoration of resting membrane potential, are energy intensive. We hypothesized that cellular mechanisms exist to maximize energy production during excitation. Here, we demonstrate that NPAS4, an immediate early basic helix-loop-helix (bHLH)-PAS transcription factor, acts to maximize energy production by…
Read More
ProtoKinetix, Incorporated is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under the direction of principal investigator Dr. Kelly McNagny, Professor, Faculty of Medicine, Department of Medical Genetics. This research agreement is to test and determine the effect of AAGP™ on monoclonal antibody production and bone marrow recovery. The University of…
Read More

Dr. Martin Gleave Appointed to the Order of Canada

Director of the Vancouver Prostate Centre recognized for his leadership in prostate cancer research. Dr. Martin Gleave was recently named a member of the Order of Canada, one of the country’s highest civilian honours, for his leadership role in developing new treatments for prostate cancer and for his research on the mechanisms involved in the development of treatment resistance in cancer.…
Read More